BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Gleevec imatinib: Phase III data

Researchers from INSERM and colleagues reported data from the first part of the open-label, international Phase III SPIRIT trial in the New England Journal of Medicine showing that 400 mg/day Gleevec plus 90 µg/week Pegasys peginterferon alfa-2a resulted in significantly higher MMR rates compared with 400 or 600 mg/day Gleevec monotherapy or 400 mg Gleevec plus cytarabine at 12 months (57% vs. 38%, 49% and 46%, respectively, p<0.001 across all...

Read the full 338 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >